Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
genentech
9
×
life sciences
national blog main
national top stories
new york top stories
9
×
san francisco top stories
biotech
boston blog main
boston top stories
national
new york blog main
san diego blog main
san diego top stories
san francisco blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
celgene
bristol-myers squibb
clinical trials
eli lilly
fda
pfizer
cancer
deals
gene therapy
ipo
johnson & johnson
startups
What
bio
roundup
drug
approved
fda
new
news
biotech
cancer
companies
drugs
group
known
liver
medical
pharmaceutical
today
adu
aiming
alzheimer’s
ambys
annual
appetite
atrophy
august
beats
bids
big
biogen
biopharma
black
bread
breast
busy
butter
buyout
cancer's
cash
clinical
complicated
Language
unset
Current search:
genentech
×
" new york top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?